|
|
Volumn 4, Issue 3, 2008, Pages 149-158
|
|
Technology Insight: Therapy for Duchenne muscular dystrophy - An opportunity for personalized medicine?
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2 O METHYL PHOSPHOROTHIOATED OLIGONUCLEOTIDE;
AMINOGLYCOSIDE;
ANTISENSE OLIGONUCLEOTIDE;
DNA;
DYSTROPHIN;
GENE PRODUCT;
GENTAMICIN;
MORPHOLINO OLIGONUCLEOTIDE;
OLIGODEOXYNUCLEOTIDE;
OLIGONUCLEOTIDE;
ORPHAN DRUG;
PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDE;
PTC 124;
UNCLASSIFIED DRUG;
BECKER MUSCULAR DYSTROPHY;
CLINICAL TRIAL;
DUCHENNE MUSCULAR DYSTROPHY;
GENE DELETION;
GENE MUTATION;
GENE THERAPY;
GENETIC DISORDER;
HUMAN;
NONHUMAN;
POINT MUTATION;
PRIORITY JOURNAL;
PROTEIN ANALYSIS;
REVIEW;
GENE THERAPY;
HUMANS;
MUSCULAR DYSTROPHY, DUCHENNE;
MUTATION;
TARGETED GENE REPAIR;
|
|
EID: 40549093323
PISSN: 1745834X
EISSN: 17458358
Source Type: Journal
DOI: 10.1038/ncpneuro0737 Document Type: Review |
|
Times cited : (18)
|
|
References (82)
|
